-

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by proxy are as follows:

Election of Directors

 

Director Nominees


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


WITHHELD


FOR


WITHHELD

Daniel N. Chicoine

6,490,732

109,026

98.3%

1.7%

Anthony E. Dobranowski

6,508,888

90,870

98.6%

1.4%

John C. London

6,533,190

66,568

99.0%

1.0%

Deborah Shannon-Trudeau

6,541,297

58,461

99.1%

0.9%

Serge Verreault

6,590,211

9,547

99.9%

0.1%

Reappointment of External Auditors

 

Outcome


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


WITHHELD


FOR


WITHHELD

Ernst & Young LLP reappointed

7,212,551

148,556

98.0%

2.0%

Approval of the Continuation of Crescita’s Share Incentive Plan

 

Outcome


NUMBER OF SHARES


PERCENTAGE OF VOTES CAST


FOR


AGAINST


FOR


AGAINST

Share Incentive Plan approved

6,526,477

73,281

98.9%

1.1%

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

Source: Crescita Therapeutics

Contacts

Linda Kisa, CPA, CA
Vice-President, Reporting and Corporate Affairs
Email: lkisa@crescitatx.com

Industry:

Crescita Therapeutics

TSX:CTX
Release Versions
English

Contacts

Linda Kisa, CPA, CA
Vice-President, Reporting and Corporate Affairs
Email: lkisa@crescitatx.com

More News From Crescita Therapeutics

Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) announced today that it has filed and mailed the management information circular (the “Circular”) and related materials in connection with the special meeting (the “Meeting”) of its shareholders (the “Shareholders”) to be held on May 14, 2026 in person at 2805 Place Louis-R-Renaud, Laval, Québec. The Meeting has been called for Shareholders to consider and, if deemed advisable,...

Crescita Reports Q4 and Fiscal 2025 Results

LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2025 (“Q4-2025” and “F2025”). All amounts presented are in thousands of Canadian dollars (“CAD”) unless otherwise noted and in accordance with International Financial Reporting Standards (“IFRS”) as issued b...

Crescita Announces Definitive Agreement to Be Acquired by ClinActiv Holdings in an All-Cash Transaction at a Significant Premium

LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) today announced that it has entered into a definitive arrangement agreement (the “Arrangement Agreement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its affiliate (the “Purchaser”) pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the “Shares”) in exchange for all-cash consideration (the “Arrangement”). The target pu...
Back to Newsroom